DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 minutes ago

RVMD·Revolution Medicines, Inc.

$.
-. (-.%)
After Hours
High
$192.50
Open
$192.22
Market Cap
39.83B
52W High
$193.82
Low
$184.79
P. Close
$186.89
P/E
-
52W Low
$34.00
Fwd P/E
-32.19
DailyIQ Est.
$213.71
Technical Score (1D)
82
BUY
News Sentiment
70
BULLISH
Guggenheim’s recent upgrade to a Buy and lift of the price target to $235 reflects renewed confidence in Revolution Medicines’ drug pipeline, a sentiment echoed by several other analysts. This upgrade follows the company’s phase‑3 data that showed high response rates and a manageable safety profile for its oncology lead, suggesting a potential shift in treatment for certain cancers. Meanwhile, the European Medicines Agency has entered a phased review of the pancreatic‑cancer candidate Daraxonrasib, with fast‑track designation that could shorten the time to full approval. The phased review also confirms the drug’s orphan status, which may accelerate regulatory scrutiny and market entry. In the United States, the rolling NDA for Daraxonrasib is nearing completion under the National Priority Voucher pilot, positioning the company for a dual‑market launch if approvals are granted. These developments raise the probability of regulatory milestones in the next 1–10 trading days, which could validate the higher valuation targets. Traders should monitor the upcoming earnings release for guidance on revenue expectations and any updates on the FDA review timeline. The next key watch item is the EMA Human Medicines Committee meeting schedule, as a favorable decision could unlock EU commercial prospects. Additionally, keep an eye on the FDA’s response to the rolling NDA, as a positive outcome would confirm the U.S. launch window and support the company’s growth narrative.
Earnings Summary
Revolution Medicines (RVMD) is a clinical‑stage oncology company that develops targeted therapies for RAS‑mutated cancers, with a pipeline that includes Phase 1 RAS(ON) inhibitors such as daraxonrasib and elironrasib and Phase 2 companion agents like RMC‑4630. In Q4 2024, the company reported a negative EPS of $‑1.12 versus an estimate of $‑0.96453, and generated no revenue, reflecting its pre‑commercial status; the most recent earnings data for Q2 2026 are pending, with an estimated revenue of $18.42 million and no EPS disclosed. The company has consistently missed earnings estimates in the quarters reported, underscoring the high‑risk, high‑reward nature of its development pipeline. Historically, RVMD’s financials have shown a pattern of negative earnings and zero revenue, typical for a company focused on late‑stage clinical trials rather than sales. Recent news highlights a Phase 3 data release that demonstrated unexpectedly high response rates for its lead candidate, coupled with a manageable safety profile, and the European Medicines Agency has begun a phased review of daraxonrasib for metastatic pancreatic cancer, while the U.S. FDA’s rolling NDA under the National Priority Voucher pilot is nearing completion; these regulatory milestones could accelerate market entry and unlock revenue streams. Investors should watch for the EMA’s next decision on the phased review, the FDA’s review timeline, and any subsequent clinical data releases that could influence regulatory confidence, as well as pricing and reimbursement discussions that may affect commercial viability.

EPS

EstBeatMiss
$-2.19$-1.85$-1.50$-1.15$-0.80Q4'24Q2'26
QtrEstActual+/−
Q2'26$-2.03 - -
Q4'24$-0.96$-1.12-16.1%

Revenue

EstBeatMiss
$-3M$3M$9M$15M$21MQ4'24Q2'26
QtrEstActual+/−
Q2'26$18M - -
Q4'24 - $0 -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

RVMD Stock Snapshot

RVMD is currently trading at $188.00, giving Revolution Medicines, Inc. a market cap of 39.83B. Today's range spans $184.79–$192.50, with shares opening at $192.22 and moving up $1.11 (0.6%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 70/100.

Over the past year RVMD has traded between $34.00 and $193.82 - the current price is +452.9% off the 52-week low and -3.0% from the high. 31 analysts cover the stock with a Buy consensus and a mean 12-month target of $200.27 (range $151.00–$263.00), implying upside of +6.5%.

The BUY technical setup for RVMD (82/100) is worth attention in the context of the broader Healthcare sector. At $188.00 (near 52-week highs), with 39.83B in capitalization and bullish sentiment at 70/100, this large-cap name sits at the intersection where momentum strategies and fundamental growth investors both find something to like. Annual range: $34.00–$193.82.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (82/100) and news sentiment (70/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $188.00 (near 52-week highs), RVMD's position within the $34.00–$193.82 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.